Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Oncotargets and Therapy|November 10, 2018
Clinical use of FLT3 inhibitors in acute myeloid leukemiaGrerk Sutamtewagul, Carlos E VigilCancer Control : Journal of the Moffitt Cancer Center|December 17, 2009
Current progress in targeted therapy for colorectal cancerJose Ortega, Carlos E Vigil, Catherine ChodkiewiczDrug Design, Development and Therapy|October 20, 2010
Safety and efficacy of azacitidine in myelodysplastic syndromesCarlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroBlood Reviews|March 23, 2011
Interpretation of cytogenetic and molecular results in patients treated for CMLCarlos E Vigil, Elizabeth A Griffiths, Eunice S Wang, et al.American Journal of Hematology|March 27, 2015
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years oldNeha Gupta, Austin Miller, Shipra Gandhi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2011
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic modelKiran Naqvi, Guillermo Garcia-Manero, Sagar Sardesai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2024
Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AMLEunice S Wang, Aaron D Goldberg, Martin Tallman, et al.Breast (Edinburgh, Scotland)|August 14, 2010
Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancerHenry L Gómez, Joseph A Pinto, Mivael Olivera, et al.Blood Advances|March 20, 2024
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trialsPau Montesinos, Amir T Fathi, Stéphane de Botton, et al.International Journal of Cancer|December 15, 2010
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytomaS Tariq Mahmood, Samuel Agresta, Carlos E Vigil, et al.Pageof 2